EWA
ITCI

EP Wealth Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

EP Wealth Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-7,828
Closed -$218K – 149
2016
Q1 		$218K Sell
7,828
-2,258
-22% -$75.3K 0.03% 124
2015
Q4 		$543K Buy
+10,086
New +$509K 0.09% 88

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

EP Wealth Advisors's ITCI Position: Q2 2016 in Review

EP Wealth Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2016, closing a stake of 7,828 shares — an estimated $218K sold.

EP Wealth Advisors first reported a position in ITCI in Q4 2015 and held it in 2 quarters. The position peaked at $543K in Q4 2015. 139 funds tracked by Wall St. Rank hold ITCI as of Q2 2016.

  • EP Wealth Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2016 after selling out during the quarter.
  • EP Wealth Advisors sold 7,828 Intra-Cellular Therapies Inc. shares in Q2 2016, an estimated $218K.
  • EP Wealth Advisors first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 2 quarters.
  • EP Wealth Advisors's Intra-Cellular Therapies Inc. position peaked at $543K in Q4 2015.
  • 139 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2016.

Based on EP Wealth Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.